Maxipime (MAXI-peem, cefepime), the first "fourth-generation" injectable cephalosporin

June 1996

Bristol-Myers Squibb is launching Maxipime (MAXI-peem, cefepime), the first "fourth-generation" injectable cephalosporin.

In general, the first-generation agents are primarily active against gram-positive bacteria.

Second and third generations have increasing gram-negative coverage...sometimes at the expense of reduced gram-positive activity.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

three new HIV tests
Obesity & Weight Loss safety of the popular new diet pill, Redux (dexfenfluramine)
Serzone (nefazodone) may cause less sexual dysfunction than SSRIs
Paxil (paroxetine) for panic disorder and obsessive compulsive disorder (OCD)
Multiple Sclerosis Avonex (interferon beta-1a), the new treatment for multiple sclerosis (MS)
Dermatology Lamisil (terbinafine) TABLETS for treating fungal nail infections
Infectious Diseases new 3-day Cipro Cystitis Pack
Infectious Diseases Bactroban Nasal (mupirocin ointment) to reduce the spread of MRSA
Infectious Diseases Maxipime (MAXI-peem, cefepime), the first "fourth-generation" injectable cephalosporin
Cholesterol cholesterol-lowering drug therapy almost pays for itself
patient compliance for their new protease inhibitor, Norvir (ritonavir)
ACE Inhibitors ACE inhibitors for renal disease
ACE Inhibitors new ACE inhibitor, Mavik (trandolapril)
estrogen for postpartum depression